• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 3. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 4. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 5. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azaspirodecane derivatives Azaspirodecane derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azaspirodecane derivatives

Recent Advances in the Study of 1-Oxa-4-azaspiro[5.5]undecane (CAS: 3970-87-4) and Its Applications in Chemical Biology and Pharmaceutical Research

The compound 1-Oxa-4-azaspiro[5.5]undecane (CAS: 3970-87-4) has garnered significant attention in recent years due to its unique spirocyclic structure and potential applications in medicinal chemistry and drug discovery. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, biological activity, and therapeutic potential. Recent studies have highlighted its role as a versatile scaffold for the development of novel bioactive molecules, particularly in the context of central nervous system (CNS) disorders and infectious diseases.

One of the key advancements in the synthesis of 1-Oxa-4-azaspiro[5.5]undecane involves the use of catalytic asymmetric methods to achieve high enantioselectivity. A 2023 study published in the Journal of Medicinal Chemistry demonstrated an efficient one-pot synthesis route using palladium-catalyzed cyclization, which significantly improved yield and purity compared to traditional methods. This breakthrough has facilitated the production of derivatives with enhanced pharmacological properties, paving the way for further structure-activity relationship (SAR) studies.

In terms of biological activity, 1-Oxa-4-azaspiro[5.5]undecane derivatives have shown promising results as modulators of gamma-aminobutyric acid (GABA) receptors. Preclinical studies indicate that certain analogs exhibit potent anxiolytic and anticonvulsant effects, with reduced side effects compared to existing therapeutics. Additionally, recent in vitro assays have revealed its potential as an inhibitor of bacterial efflux pumps, suggesting applications in combating antibiotic-resistant pathogens. These findings were corroborated by a 2024 Nature Chemical Biology publication, which identified specific molecular interactions responsible for its efficacy.

The therapeutic potential of 1-Oxa-4-azaspiro[5.5]undecane extends beyond CNS and antimicrobial applications. A collaborative study between academic and industry researchers, published in ACS Pharmacology & Translational Science, explored its use as a scaffold for targeted cancer therapies. By functionalizing the spirocyclic core with various pharmacophores, researchers developed compounds with selective cytotoxicity against tumor cells while sparing healthy tissues. This approach underscores the compound's versatility and adaptability in drug design.

Despite these advancements, challenges remain in optimizing the pharmacokinetic and safety profiles of 1-Oxa-4-azaspiro[5.5]undecane-based drugs. Recent toxicology studies have identified potential metabolic liabilities, prompting the development of prodrug strategies to enhance bioavailability. Furthermore, computational modeling and high-throughput screening are being employed to identify optimal derivatives for clinical translation. The integration of these techniques is expected to accelerate the progression of this compound from bench to bedside.

In conclusion, 1-Oxa-4-azaspiro[5.5]undecane (CAS: 3970-87-4) represents a promising scaffold for the development of next-generation therapeutics. Its unique structural features and diverse biological activities make it a valuable tool for addressing unmet medical needs. Continued research into its synthesis, mechanism of action, and clinical potential will undoubtedly yield further breakthroughs in the coming years. This brief underscores the importance of interdisciplinary collaboration in advancing the field of chemical biology and pharmaceutical research.

• 1807938-35-7((1S,2R,4R)-6',6'-dimethylspiro[bicyclo[2.2.1]heptane-2,2'-morpholine])
• 1559914-99-6(spirobicyclo2.2.1heptane-2,2'-morpholine)
• 1354951-87-3(1-oxa-4-azaspiro[5.5]undecane hydrochloride)
• 1559261-83-4(6',6'-dimethylspirobicyclo2.2.1heptane-2,2'-morpholine)
• 2411249-40-4(1-Oxa-4-azaspiro[5.5]undecan-9-ol;hydrochloride)
• 220291-94-1(1-oxa-4-azaspiro[5.6]dodecane)
• 220291-93-0(5-Oxa-8-azaspiro[3.5]nonane)
• 1018608-06-4(7-methyl-6-oxa-9-azaspiro4.5decane)
• 1018639-87-6(2-methyl-1-oxa-4-azaspiro5.5undecane)
• 130643-07-1(6-Oxa-9-azaspiro[4.5]decane)